Efficacy and safety of the long-acting C5 inhibitor ravulizumab in patients with atypical hemolytic uremic syndrome triggered by pregnancy: a subgroup analysis

  1. Gäckler, A.
  2. Schönermarck, U.
  3. Dobronravov, V.
  4. La Manna, G.
  5. Denker, A.
  6. Liu, P.
  7. Vinogradova, M.
  8. Yoon, S.-S.
  9. Praga, M.
Journal:
BMC Nephrology

ISSN: 1471-2369

Year of publication: 2021

Volume: 22

Issue: 1

Type: Article

DOI: 10.1186/S12882-020-02190-0 GOOGLE SCHOLAR lock_openOpen access editor